Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+4.5%		$0.01
$0.00
▼
$0.56
$96K-9.0866,740 shs583 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
-10.3%		$0.00
$0.00
▼
$0.03
$109K1.88110,061 shs5,266 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-4.35%-12.00%-47.62%+2,100.00%-99.08%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
+39.29%+21.88%-15.22%-39.06%-86.78%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
$0.18
$0.18
$0.00
▼
$0.64
$208K5.962,326 shsN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$0.00
+4.5%		$0.01
$0.00
▼
$0.56
$96K-9.0866,740 shs583 shs
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$0.00
-10.3%		$0.00
$0.00
▼
$0.03
$109K1.88110,061 shs5,266 shs
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$0.03
$0.04
$0.00
▼
$14.75
$110K1.37120,908 shsN/A
7 Best Space Stocks to Own in 2026 Cover
7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00%0.00%0.00%0.00%+6,681.48%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-4.35%-12.00%-47.62%+2,100.00%-99.08%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
+39.29%+21.88%-15.22%-39.06%-86.78%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
0.00
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
1.00
SellN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
0.00
N/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/A$4.04 per shareN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
$10.77M0.01N/AN/A($0.67) per share0.00
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
$5.11M0.02N/AN/A$4.04 per share0.00
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
$12.05M0.01$1.61 per share0.02($0.37) per share-0.09
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
-$60.48M$0.730.00N/AN/A-254.28%N/A-192.17%11/5/2026 (Estimated)
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
-$8.16M-$0.36N/AN/AN/AN/A-78.22%-23.50%N/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/AN/AN/AN/AN/A
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
N/AN/AN/AN/AN/A
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
N/AN/AN/A
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
N/A
0.48
0.48
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
1.58
0.85
0.74
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
N/A
0.66
0.66

Institutional Ownership

CompanyInstitutional Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
5.73%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
44.27%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.34%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
11.61%

Insider Ownership

CompanyInsider Ownership
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
3.30%
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
6.90%
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
12.25%
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
5.27%
CompanyEmployeesShares OutstandingFree FloatOptionable
Ampio Pharmaceuticals, Inc. stock logo
AMPE
Ampio Pharmaceuticals
201.14 million1.10 millionNo Data
Carisma Therapeutics Inc. stock logo
CARM
Carisma Therapeutics
2041.85 million38.91 millionNo Data
Petros Pharmaceuticals, Inc. stock logo
PTPI
Petros Pharmaceuticals
2031.16 million9.93 millionNot Optionable
TRACON Pharmaceuticals, Inc. stock logo
TCON
TRACON Pharmaceuticals
203.41 million3.23 millionNo Data

Recent News About These Companies

TRACON Pharma (OTC:TCON) Stock, Short Interest Report
October 5, 2024  |  benzinga.comhttps://www.benzinga.com/quote/TCON/short-interest
TRACON Pharmaceuticals Announces it Will Wind Down Operations
July 30, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/07/30/2921433/10391/en/tracon-pharmaceuticals-announces-it-will-wind-down-operations.html
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
June 11, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/06/11/2896712/10391/en/tracon-announces-publication-in-clinical-cancer-research-of-phase-2-clinical-data-for-trc102-a-dna-damage-repair-inhibitor-in-recurrent-glioblastoma-patients.html
TRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?
May 27, 2024  |  bovnews.comB
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call Transcript
May 15, 2024  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/tracon-pharmaceuticals-inc-nasdaqtcon-q1-2024-earnings-call-transcript/ar-BB1mqOyK
Q1 2024 TRACON Pharmaceuticals Inc Earnings Call
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/q1-2024-tracon-pharmaceuticals-inc-105310624.html?.tsrc=rss
TRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
May 15, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-inc-tcon-q1-071015646.html?.tsrc=rss
TCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024
May 14, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/05/tcon-stock-earnings-tracon-pharma-for-q1-of-2024/?utm_source=Tradesmith&utm_medium=referral
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/tracon-pharmaceuticals-reports-first-quarter-200100042.html
Tracon: Q1 Earnings Snapshot
May 14, 2024  |  timesunion.comT
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/14/2881830/10391/en/tracon-pharmaceuticals-reports-first-quarter-2024-financial-results-and-provides-corporate-update.html
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
May 7, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/05/07/2877173/10391/en/tracon-to-report-first-quarter-2024-financial-results-and-provide-corporate-update-on-may-14-2024.html
TRACON Pharmaceuticals Inc
April 26, 2024  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tcon-tracon-pharmaceuticals-inc/vitals
Buy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation Update
April 10, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-reaffirmed-for-tracon-pharmaceuticals-post-reverse-split-and-envafolimab-valuation-update-1033238463
TRACON announces 1-for-20 reverse stock split
April 10, 2024  |  uk.investing.comhttps://uk.investing.com/news/stock-market-news/tracon-announces-1for20-reverse-stock-split-93CH-3422554
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
April 10, 2024  |  investorplace.comhttps://investorplace.com/2024/04/wall-street-favorites-3-penny-stocks-with-strong-buy-ratings-for-april-2024/
Shares of Tracon Pharmaceuticals Tumble 22% on Reverse Split
April 8, 2024  |  marketwatch.comhttps://www.marketwatch.com/story/shares-of-tracon-pharmaceuticals-tumble-22-on-reverse-split-997bdc19
TRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-04/61890558-tracon-pharmaceuticals-inc-tracon-pharmaceuticals-announces-reverse-stock-split-399.htm
TRACON Pharmaceuticals Announces Reverse Stock Split
April 8, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/04/08/2859242/10391/en/tracon-pharmaceuticals-announces-reverse-stock-split.html
Buy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial Outlook
April 4, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-tracon-pharmaceuticals-amid-promising-envafolimab-trial-outlook-1033220294

New MarketBeat Followers Over Time

Ampio Pharmaceuticals stock logo

Ampio Pharmaceuticals NYSE:AMPE

$0.18 0.00 (0.00%)
As of 08/18/2026

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.

Carisma Therapeutics stock logo

Carisma Therapeutics NASDAQ:CARM

$0.0023 +0.00 (+4.55%)
As of 11:40 AM Eastern

Carisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.

Petros Pharmaceuticals stock logo

Petros Pharmaceuticals NASDAQ:PTPI

$0.0035 0.00 (-10.26%)
As of 10:57 AM Eastern

Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics in the United States and internationally. It operates through two segments, Prescription Medications and Medical Devices. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a novel and patented topical formulation candidate for the treatment of acute Peyronie's disease. The company offers men's health products, including vacuum erection devices, penile injections, PreBoost, VenoSeal, and urinary tract infection tests for the treatment of erectile dysfunction. Petros Pharmaceuticals, Inc. is based in New York, New York.

TRACON Pharmaceuticals stock logo

TRACON Pharmaceuticals NASDAQ:TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas